rs61731652
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_017433.5(MYO3A):āc.949G>Cā(p.Ala317Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000536 in 1,614,022 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_017433.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYO3A | NM_017433.5 | c.949G>C | p.Ala317Pro | missense_variant | 10/35 | ENST00000642920.2 | NP_059129.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYO3A | ENST00000642920.2 | c.949G>C | p.Ala317Pro | missense_variant | 10/35 | NM_017433.5 | ENSP00000495965 | P1 | ||
MYO3A | ENST00000543632.5 | c.949G>C | p.Ala317Pro | missense_variant | 9/17 | 1 | ENSP00000445909 | |||
MYO3A | ENST00000642197.1 | n.1153G>C | non_coding_transcript_exon_variant | 10/27 | ||||||
MYO3A | ENST00000647478.1 | c.949G>C | p.Ala317Pro | missense_variant, NMD_transcript_variant | 9/30 | ENSP00000493932 |
Frequencies
GnomAD3 genomes AF: 0.00296 AC: 450AN: 152168Hom.: 3 Cov.: 33
GnomAD3 exomes AF: 0.000716 AC: 180AN: 251258Hom.: 0 AF XY: 0.000427 AC XY: 58AN XY: 135806
GnomAD4 exome AF: 0.000283 AC: 414AN: 1461736Hom.: 0 Cov.: 31 AF XY: 0.000231 AC XY: 168AN XY: 727176
GnomAD4 genome AF: 0.00296 AC: 451AN: 152286Hom.: 3 Cov.: 33 AF XY: 0.00287 AC XY: 214AN XY: 74470
ClinVar
Submissions by phenotype
Autosomal recessive nonsyndromic hearing loss 30 Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Dec 17, 2020 | - - |
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 02, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | May 12, 2021 | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 17, 2021 | The c.949G>C (p.A317P) alteration is located in exon 10 (coding exon 8) of the MYO3A gene. This alteration results from a G to C substitution at nucleotide position 949, causing the alanine (A) at amino acid position 317 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 15, 2017 | p.Ala317Pro in exon 10 of MYO3A: This variant is not expected to have clinical s ignificance because it has been identified in 1.1% (112/10288) of African chromo somes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs61731652). - |
MYO3A-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 23, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at